Lithium carbonate
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
Warning
See full prescribing information for complete Boxed Warning.
Condition Name:
Lithium toxicity is closely related to serum lithium levels and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see dosage and administration).
|
Overview
Lithium carbonate is a mood Stabilizer that is FDA approved for the {{{indicationType}}} of bipolar disorder, maintenance therapy and manic episode. There is a Black Box Warning for this drug as shown here. Common adverse reactions include acne, hypothyroidism, weight increased, gastritis, nausea, xerostomia, leukocytosis, fine tremor, hyperreflexia, deep tendon, nephrotoxicity, polyuria, increased thirst.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Bipolar disorder, maintenance therapy
- Maintenance 900 to 1200 mg/day PO in 2 to 3 divided doses
- Bipolar disorder, manic episode
- 1800 mg/day PO in 2 to 3 divided doses
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information about Off-Label Guideline-Supported Use of Lithium carbonate in adult patients.
Non–Guideline-Supported Use
There is limited information about Off-Label Non–Guideline-Supported Use of Lithium carbonate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- Safety below the age of 12 have not been established.
- Bipolar disorder, maintenance therapy
- 12 yr and older, extended-release tablets, maintenance, 900 to 1200 mg/day PO in 2 to 3 divided doses; desired serum lithium levels ranging between 0.6 to 1.2 mEq/L
- Bipolar disorder, maintenance therapy
- Immediate-release tablet and capsule formulations, maintenance, 300 mg PO 3 to 4 times daily
Bipolar disorder, manic episode
- 12 yr and older, extended-release tablets, acute mania, 1800 mg/day PO in 2 to 3 divided doses
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information about Off-Label Guideline-Supported Use of Lithium carbonate in pediatric patients.
Non–Guideline-Supported Use
There is limited information about Off-Label Non–Guideline-Supported Use of Lithium carbonate in pediatric patients.
Contraindications
There is limited information regarding Lithium carbonate Contraindications in the drug label.
Warnings
|
Warning
See full prescribing information for complete Boxed Warning.
Condition Name:
Lithium toxicity is closely related to serum lithium levels and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see dosage and administration).
|
Lithium Toxicity
Lithium toxicity is closely related to serum lithium levels and can occur at doses close to therapeutic levels. Outpatients and their families should be warned that the patient must discontinue lithium carbonate therapy and contact his physician if such clinical signs of lithium toxicity as diarrhea, vomiting, tremor, mild ataxia, drowsiness or muscular weakness occur. Lithium carbonate may impair mental and/or physical abilities. Caution patients about activities requiring alertness (e.g., operating vehicles or machinery). Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration or sodium depletion, since the risk of lithium toxicity is very high in such patients. If the psychiatric indication is life threatening and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.
Unmasking of Brugada Syndrome
There have been post-marketing reports of a possible association between treatment with lithium and the unmasking of Brugada Syndrome. Brugada Syndrome is a disorder characterized by abnormal electrocardiographic (ECG) findings and a risk of sudden death. Lithium should generally be avoided in patients with Brugada Syndrome or those suspected of having Brugada Syndrome. Consultation with a cardiologist is recommended if: (1) treatment with lithium is under consideration for patients suspected of having Brugada Syndrome or patients who have risk factors for Brugada Syndrome, e.g., unexplained syncope, a family history of Brugada Syndrome, or a family history of sudden unexplained death before the age of 45 years, (2) patients who develop unexplained syncope or palpitations after starting lithium therapy.
Renal Effects
Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia. Such patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued. Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in manic depressive patients never exposed to lithium. The relationship between renal functional and morphologic changes and their association with lithium therapy have not been established. When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.
Encephalopathic Syndrome
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN and FBS) has occurred in a few patients treated with lithium plus a neuroleptic. In some instances, the syndrome was followed by irreversible brain damage. Because of a possible causal relationship between these events and the concomitant administration of lithium and neuroleptics, patients receiving such combined therapy should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. This encephalopathic syndrome may be similar to or the same as neuroleptic malignant syndrome (NMS).
Concomitant Use with Neuromuscular Blocking Agents
Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium. Usage in Pregnancy Adverse effects on implantation in rats, embryo viability in mice and metabolism in vitro of rat testes and human spermatozoa have been attributed to lithium, as have teratogenicity in submammalian species and cleft palates in mice. In humans, lithium carbonate may cause fetal harm when administered to a pregnant woman. Data from lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein’s anomaly. If this drug is used in women of childbearing potential, or during pregnancy, or if a patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Usage in Nursing Mothers
Lithium is excreted in human milk. Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.
Usage in Pediatric Patients
Since information regarding the safety and effectiveness of lithium carbonate in children under 12 years of age is not available, its use in such patients is not recommended. There has been a report of a transient syndrome of acute dystonia and hyperreflexia occurring in a 15 kg child who ingested 300 mg of lithium carbonate.
Usage in the Elderly
Elderly patients often require lower lithium dosages to achieve therapeutic serum levels. They may also exhibit adverse reactions at serum levels ordinarily tolerated by younger patients.
General precautions
The ability to tolerate lithium is greater during the acute manic phase and decreases when manic symptoms subside.
The distribution space of lithium approximates that of total body water. Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of lithium is proportional to its plasma concentration. The half-life of elimination of lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to sodium depletion. Therefore, it is essential for the patient to maintain a normal diet, including salt and an adequate fluid intake (2,500 mL to 3,000 mL) at least during the initial stabilization period. Decreased tolerance to lithium has been reported to ensue from protracted sweating or diarrhea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved.
In addition to sweating and diarrhea, concomitant infection with elevated temperatures may also necessitate a temporary reduction or cessation of medication.
Previously existing underlying thyroid disorders do not necessarily constitute a contraindication to lithium treatment; where hypothyroidism exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any; where hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Lithium carbonate Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Lithium carbonate Postmarketing Experience in the drug label.
Drug Interactions
Caution should be used when lithium and diuretics are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of lithium toxicity. Patients receiving such combined therapy should have serum lithium levels monitored and the lithium dosage adjusted if necessary. Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, lithium toxicity has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations. There is also evidence that other non-steroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg b.i.d. with celecoxib 200 mg b.i.d. as compared to subjects receiving lithium alone. Concurrent use of metronidazole with lithium may provoke lithium toxicity due to reduced renal clearance. Patients receiving such combined therapy should be monitored closely. There is evidence that angiotensin-converting enzyme inhibitors, such as enalapril and captopril and angiotension II receptor antagonists, such as losartan, may substantially increase steady-state plasma lithium levels, sometimes resulting in lithium toxicity. When such combinations are used, lithium dosage may need to be decreased and plasma lithium levels should be measured more often. Concurrent use of calcium channel blocking agents with lithium may increase the risk of neurotoxicity in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. Caution is recommended. The concomitant administration of lithium with selective serotonin reuptake inhibitors should be undertaken with caution as this combination has been reported to result in symptoms such as diarrhea, confusion, tremor, dizziness and agitation. The following drugs can lower serum lithium concentrations by increasing urinary lithium excretion: acetazolamide, urea, xanthine preparations and alkalinizing agents such as sodium bicarbonate. The following have also been shown to interact with lithium: methyldopa, phenytoin and carbamazepine.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Lithium carbonate in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Lithium carbonate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Lithium carbonate during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Lithium carbonate in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Lithium carbonate in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Lithium carbonate in geriatric settings.
Gender
There is no FDA guidance on the use of Lithium carbonate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Lithium carbonate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Lithium carbonate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Lithium carbonate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Lithium carbonate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Lithium carbonate in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Lithium carbonate Administration in the drug label.
Monitoring
There is limited information regarding Lithium carbonate Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Lithium carbonate and IV administrations.
Overdosage
There is limited information regarding Lithium carbonate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Lithium carbonate Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Lithium carbonate Mechanism of Action in the drug label.
Structure
There is limited information regarding Lithium carbonate Structure in the drug label.
Pharmacodynamics
There is limited information regarding Lithium carbonate Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Lithium carbonate Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Lithium carbonate Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Lithium carbonate Clinical Studies in the drug label.
How Supplied
There is limited information regarding Lithium carbonate How Supplied in the drug label.
Storage
There is limited information regarding Lithium carbonate Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Lithium carbonate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Lithium carbonate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Lithium carbonate Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Lithium carbonate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Lithium carbonate Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Lithium carbonate Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.